Altered extracellular matrix (ECM) protein deposition is a feature in asthmatic airways. 37 Fibronectin (Fn), an ECM protein produced by human bronchial epithelial cells (HBECs), is 38 increased in asthmatic airways. This study investigated the regulation of Fn production in 39 asthmatic or non-asthmatic HBECs, and whether Fn modulated HBEC proliferation and 40 inflammatory mediator secretion. The signaling pathways underlying transforming growth 41 factor (TGF)-β1 regulated Fn production were examined using specific inhibitors for ERK, 42 JNK, p38 MAPK, phosphatidylinositol (PI)3 kinase and activin like kinase (ALK)5. proliferation and IL-6 release, decreased PGE 2 secretion, but had no effect on VEGF release. 51
Introduction
Cell number, viability and cytotoxicity assay 213 At the end point of experiments, the cell number, viability and cytotoxicity were determined 214 using manually cell counting, a lactate dehydrogenase (LDH) assay and/or a mitochondrial 215 activity assay (MTT) respectively. The LDH assay was a means of measuring either the 216 number of cells via total cytoplasmic LDH or membrane integrity (cytotoxicity) as a function 217 of the amount of cytoplasmic LDH released into the medium. The MTT assay was a means of 218 measuring the activity of living cells via mitochondrial dehydrogenases. Both assays were 219 carried out according the manufacturer's instructions (Sigma, Saint Louis, Missouri). The 220 absorbance was measured using the SpectraMax M2 microplate reader. The data from each 221 treatment were averaged and background absorbance subtracted and GraphPad Prism 222 (Version 5.0) was used for further analysis. 223
224
The cell proliferation status and membrane integrity were also confirmed using CyQUANT 225
Direct Cell Proliferation Assay according to the manufacturer's instructions (Molecular 226
Probes, Eugene, Oregon). 227
228

Statistical analysis
229
Data were expressed as mean ± the standard error of the mean (SEM) for the number of HBE 230 cell cultures (n) stated and analysed using GraphPad Prism (Version 6.0). After testing for 231 normal distribution and equal variance, the differences were assessed by unpaired Student's t 232 test, one-way or two-way ANOVA using Dunnett's or Sidak's multiple comparisons test or 233
Bonferroni post tests with repeated measures as appropriate. A p-value of less than 0.05 was 234 considered statistically significant. 235
Results
237
The expression of Fn from HBE cells under basal conditions 238 The levels of Fn mRNA expression were similar between asthmatic and non-asthmatic cells 239 at day 0 and 1 (Fig. 1a) . There was an increase in cell viability/proliferation measured by 240
MTT assay and soluble Fn release from asthmatic HBE cells at day 3, but no differences in 241
soluble Fn release and cell number were seen when comparing the asthmatic and non-242 asthmatic cells at days 1, 2 and 3 ( Fig. 1b and Fig. 1d ). However, asthmatic HBE cells 243 constitutively deposited greater amounts of ECM Fn than NA cells (Fig. 1c) . 244
245
TGFβ1 increased Fn production from HBE cells
246
Following stimulation with TGFβ1 the Fn mRNA expression was increased after 8 h, 247 maximal at 24 h and while beginning to decline from maximum the levels were still above 248 baseline at 48 and 72 h (n = 4, data not shown). Interestingly, after 24 h stimulation with 249 TGFβ1, non-asthmatic HBE cells expressed a greater amount of Fn mRNA compared to 250 asthmatic cells (Fig 2a) . TGFβ1 increased both soluble and ECM Fn expression after 2 days 251 of stimulation in non-asthmatic and asthmatic HBE cells. Furthermore, the levels of ECM Fn 252 produced by asthmatic cells were higher than those by non-asthmatic cells in the presence of 253 TGFβ1 ( Fig. 2b and c for day 3, data for day1 and 2 not shown), although the percentage of 254 increase in ECM Fn induced by TGFβ1 was similar in non-asthmatic and asthmatic cells (at 255 day 3, 5 ng/ml of TGFβ1, percentage increase over unstimulated 220.3 ± 54.6 % for NA n = 256 7, 206.3 ± 44.0 % for A n = 5, respectively). 257
258
The HBE cell viability and numbers modulated by TGFβ1 were monitored using MTT and 259
CyQUANT direct cell proliferation assay. TGFβ1 reduced cell mitochondrial activity at day 260 1, 2 and 3 in non-asthmatic and asthmatic cells (Fig 3a) . It also decreased DNA-bound 261 fluorescence intensity in both cell groups (Fig 3b) The inhibitors for ERK (PD98058), PI3 kinase (LY294002), JNK (SP600125), p38 MAP 266 kinase (SB239063) and ALK5 (SB431542) were used to block individual signaling pathways 267 which may be involved in the TGFβ1 induced ECM Fn deposition in HBE cells. PD98059, 268 LY294002, SP600125 and SB239063 had no effect on ECM Fn deposition in the absence and 269 presence of TGFβ1 in either non-asthmatic or asthmatic HBE cells (Fig 4c, d , e and f). 270
However, SB431542 inhibited TGFβ1 induced Fn mRNA expression in non-asthmatic and 271 asthmatic HBE cells (Fig 4a) . Furthermore, SB431542 blocked TGFβ1 stimulated ECM Fn 272 deposition but had no influence on constitutive ECM Fn deposition in either non-asthmatic or 273 asthmatic cells (Fig 4b) . (1) plasma Fn was precoated on the plates and the cells were seeded on top of the Fn; (2) the 280 cells were grown to confluence and quiesced before plasma Fn was added as a stimulus. 281
282
When HBE cells were seeded on the plate precoated with Fn, Fn increased cell viability at 283 day 1, 2 and 3 as measured by MTT (Fig 5a for day 2 in asthmatic and non-asthmatic cells, 284 day1 and 3 data not shown) and LDH (table 2) assay. The precoated Fn induced HBE cell 285 proliferation (Fig 5b) and this was also confirmed using a CyQUANT direct cell proliferation 286 assay (table 2) . Furthermore, the rates of cell proliferation measured by MTT, LDH, cellcounting and CyQUANT assay were similar (table 2). Precoated Fn had no effect on 288 cytotoxicity of HBE cells as measured by released LDH (n = 12, data not shown). In contrast, soluble Fn when added to confluent HBE cells had no effect on cell viability and 296 proliferation, nor did it affect cytotoxicity (non-asthmatic n = 8 and asthmatic n = 3 for MTT 297
and LDH assays, non-asthmatic n = 7 and asthmatic n = 4 for cell counting, data not shown). 298
Similarly, soluble Fn did not alter the regulation of IL-6, PGE2 and VEGF release in HBE 299 cells (non-asthmatic n = 9 and asthmatic n = 3 for IL-6 and VEGF release, non-asthmatic n = 300 5 and asthmatic n = 3 for PGE 2 release, data not shown). 301 The differences in Fn expression between non-asthmatic and asthmatic HBE cells detected in 327 this study were not consistent with the findings reported by Kicic and colleagues. In their 328 study, healthy nonatopic bronchial epithelial cells produced higher levels of Fn mRNA, 329 soluble and cell lysate Fn than atopic asthmatic cells (23). The differences between these two 330 studies may be due to the different tissue sources. In the current study, HBE cells were 331 obtained from adults with or without asthma; in Kicic's study, the epithelial cells were 332 collected from children with or without asthma. It is of interest that there was a differential 333 expression of Fn by HBE cells derived from adults and children. Other studies also found the 334 discrepant results when comparing cellular responses from cells from children and adults in 335 growth factor release and ECM deposition when comparing asthmatic and non-asthmatic 336 airways (12, 24, 45) (8)(5, 44). The findings from these studies indicate that thecharacteristics of asthmatic HBE cells and the ECM proteins deposited in asthmatic airways 338 are altered. However, the alterations in asthmatic airways may be different between adults 339 and children but this requires further investigation to understand the mechanisms underlying 340 these changes. 341
342
The current study found that TGFβ1 augmented both soluble and ECM Fn production by 343 asthmatic and non-asthmatic HBE cells; and the increase was at least partly regulated at the 344 level of transcription since TGFβ1 also induced Fn mRNA expression. These results were 345 consistent with the study conducted by Doerner and coworkers (6) . 346 347 In this study, specific inhibitors for ERK, JNK, PI3K, p38 MAP kinase and TGFβ type I 348 receptor ALK-5 were used to test which signaling pathways were involved in basal and 349 The MTT and CyQUANT direct cell proliferation assays were used in this study to measure 366 the cell number, viability and membrane integrity in TGFβ1 treated cells. The MTT assay is 367 based on intracellular proteinase activities which can represent cell numbers in most 368 conditions (4, 26, 31, 35, 42) . The limitation of the MTT assay is that some treatments may 369 influence certain enzyme activities which could affect the MTT measurement but have no 370 effect on the live cell number or the mitochondrial activity per cell (49). In the current study, 371
TGFβ1 reduced MTT measurements in both asthmatic and non-asthmatic HBE cells. The 372
CyQUANT assay further confirmed that TGFβ1 decreased DNA content in non-asthmatic 373 HBE cells. These data indicated that TGFβ1 was not a proliferative stimulus for HBE cells in 374 the current treatment period. These results are consistent with the report by Semlali that 375 TGFβ1 does not affect baseline proliferation in asthmatic and non-asthmatic HBE cells (40) . 376
377
The role of coated Fn in epithelial cell proliferation has been reported previously in the 378 bronchial cell lines BEAS-2B and 16-HBE (11). This current study found that precoating the 379 culture vessel with Fn induced primary HBE cell proliferation in both asthmatic and non-380 asthmatic groups. This was determined using both the metabolic enzyme activity assays and 381 DNA quantification assay, and confirmed by direct cell counting. The rates of increased 382 proliferation in the presence of precoated Fn were similar in the four different measurements 383 which demonstrated that quantification of DNA is a simple and reliable method to measure 384 epithelial cell proliferation. In ASM cells, prolonged TGFβ1 (longer than 3 days) treatment 385 promotes ASM cell proliferation via interaction between TGFβ1 induced ECM proteins, 386
including Fn, and the integrin receptor α5β1 (29, 32, 48) . In this study, despite the fact that Deposited Fn modulated cell proliferation and proinflammatory cytokine and mediator 432 release in HBE cells (Fig 7) 
